Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 7/20 | 0.34 |
| ▸ | KAT7 | O95251 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28018957 | 0.70 | PKM (0.50) | GAAPKMPOLB | |
| SCHEMBL29391601 | 0.69 | GAA (0.54) | GAAPKMPOLB | |
| SCHEMBL24254286 | 0.69 | GAA (0.54) | GAAPKMPOLB | |
| SCHEMBL6582500 | 0.69 | GAA (0.54) | GAAPKMPOLBGRM4 | |
| SCHEMBL30352605 | 0.68 | POLB (0.51) | GAAPKMPOLB | |
| SCHEMBL27970026 | 0.68 | GAA (0.34) | GAAPKMPOLB | |
| SCHEMBL27970028 | 0.67 | GAA (0.33) | GAAPKMPOLB | |
| SCHEMBL19204884 | 0.67 | GAA (0.62) | GAAPKMPOLBGRM4KAT6A | |
| SCHEMBL4254051 | 0.67 | POLB (0.54) | GAAPKMPOLB | |
| SCHEMBL22494207 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104024251-B | Benzenesulfonamide compounds and their use as therapeutic agents | 克赛农制药股份有限公司 | 2017-08-11 | — | — | CN | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| EP-2773637-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | GAA 1392/4885PKM 659/4885POLB 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.